Coya Therapeutics, Inc. Common Stock
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration int… Read more
Coya Therapeutics, Inc. Common Stock (COYA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.041x
Based on the latest financial reports, Coya Therapeutics, Inc. Common Stock (COYA) has a cash flow conversion efficiency ratio of -0.041x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.13 Million) by net assets ($27.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Coya Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Coya Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Coya Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Coya Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Unitika Ltd
PINK:UNIKF
|
0.068x |
|
Trabzonspor Sportif Yatirim ve Futbol Isletmeciligi Ticaret AS
IS:TSPOR
|
0.651x |
|
ROUTE MOBILE LIMITED
NSE:ROUTE
|
0.017x |
|
Outbrain Inc
NASDAQ:OB
|
0.184x |
|
Visiomed Group SA
PINK:VMDGF
|
-0.003x |
|
Bursa De Valori Bucuresti SA
RO:BVB
|
0.021x |
|
Horizon Minerals Ltd
AU:HRZ
|
-0.107x |
|
Biomea Fusion Inc
NASDAQ:BMEA
|
-0.780x |
Annual Cash Flow Conversion Efficiency for Coya Therapeutics, Inc. Common Stock (2020–2024)
The table below shows the annual cash flow conversion efficiency of Coya Therapeutics, Inc. Common Stock from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $39.58 Million | $-10.29 Million | -0.260x | +17.20% |
| 2023-12-31 | $35.64 Million | $-11.19 Million | -0.314x | -136.40% |
| 2022-12-31 | $-8.39 Million | $-7.24 Million | 0.862x | +180.51% |
| 2021-12-31 | $3.64 Million | $-3.90 Million | -1.071x | -2172.96% |
| 2020-12-31 | $8.30 Million | $-391.27K | -0.047x | -- |